Sionna Therapeutics, INC Schedule 13D activist filings

OrbiMed Advisors and OrbiMed Capital GP VIII have reduced their beneficial ownership in Sionna Therapeutics, Inc. by selling shares via a 10b5-1 plan.

RA Capital Management and its affiliates report a dilution of their beneficial ownership in Sionna Therapeutics, Inc. to 22.6% of common stock outstanding.

Atlas Venture entities have reduced their collective beneficial ownership in Sionna Therapeutics, Inc. to 7.0% through recent share sales.

TPG GP A, LLC and its principals, James G. Coulter and Jon Winkelried, have disclosed a significant 15.2% beneficial ownership in Sionna Therapeutics, Inc. following the company's recent Initial Public Offering.

Atlas Venture entities have filed a Schedule 13D, revealing a collective 8.4% beneficial ownership in Sionna Therapeutics, primarily acquired prior to and during the company's recent initial public offering.

RA Capital Management and its affiliates have filed a Schedule 13D, revealing a significant 23.7% beneficial ownership in Sionna Therapeutics, Inc. common stock following the company's recent Initial Public Offering.

Enavate Sciences GP, LLC and Sionna Aggregator, LP have disclosed a 5.6% beneficial ownership stake in Sionna Therapeutics, Inc. following the company's initial public offering.

OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC have filed a Schedule 13D, revealing a beneficial ownership of 8.4% of Sionna Therapeutics, Inc.'s common stock, acquired through pre-IPO investments and participation in the initial public offering.